Multivariate analysis of the CPI cohort
| Variables . | OS . | PFS . | RI . | NRM . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Age | ||||||||
| 1 year increase | 1.03(1.02-1.04) | <.0001 | 1.03(1.02-1.04) | <.0001 | — | — | 1.03(1.02-1.05) | <.0001 |
| Year of HCT | ||||||||
| 1 year increase | 1.05 (0.94-1.18) | .36319 | 1 (0.9-1.1) | .94469 | — | — | 1 (0.87-1.14) | .9598 |
| Sex | ||||||||
| Female vs male | — | — | — | — | — | — | — | — |
| Donor type (ref = HLA-id sib) | ||||||||
| Haploidentical donor | 1.73 (0.98-3.05) | .05682 | — | — | — | — | — | — |
| HLA-MUD | 0.87 (0.53-1.45) | .59567 | — | — | — | — | — | — |
| Prior auto | ||||||||
| Yes vs no | — | — | — | — | — | — | — | — |
| Disease status (ref = CR) | ||||||||
| PR | 1.66(1.12-2.48) | .01179 | 1.46(1.02-2.08) | .03893 | 1.48 (0.84-2.62) | .17789 | — | — |
| Refractory | 2(1.25-3.18) | .00374 | 1.82(1.2-2.77) | .00521 | 3.03(1.66-5.56) | .00033 | — | — |
| Conditioning | ||||||||
| MAC vs RIC/NMA | 1.23 (0.78-1.94) | .37907 | — | — | — | — | — | — |
| GVHD prevention (ref = post-Cy ± other[s]) | ||||||||
| CNI + MMF or MTX ± other(s) (except post-Cy) | 1.84(1.09-3.12) | .0223 | 1.29 (0.94-1.78) | .10962 | — | — | 1.33 (0.87-2.02) | .18293 |
| KPS | ||||||||
| <90 vs ≥90 | — | — | — | — | 1.85(1.1-3.1) | .02027 | — | — |
| HCT-CI (ref = 0) | ||||||||
| 1-2 | — | — | — | — | — | — | — | — |
| ≥3 | — | — | — | — | — | — | — | — |
| Variables | aGVHD 2-4 | aGVHD 3-4 | cGVHD | Engraftment | ||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Age | ||||||||
| 1 year increase | — | — | — | — | 1.01 (1-1.03) | .0466 | 0.99 (0.99-1) | .04942 |
| Year of HCT | ||||||||
| 1 year increase | — | — | 1.03 (0.9-1.17) | .66482 | 1.03 (0.92-1.15) | .57891 | 1.18 (0.98-1.43) | .08193 |
| Sex | ||||||||
| Female vs male | — | — | 0.81 (0.5-1.3) | .37633 | — | — | — | — |
| Donor type (ref = HLA-id sib) | ||||||||
| Haploidentical donor | 2.1(1.37-3.22) | .00063 | — | — | — | — | — | — |
| HLA-MUD | 0.91 (0.6-1.38) | .65396 | — | — | — | — | — | — |
| Prior auto | ||||||||
| Yes vs no | 0.67 (0.51-0.9) | .007 | — | — | — | — | 1.18 (0.98-1.43) | .08193 |
| Disease status at conditioning (ref = CR) | ||||||||
| PR | — | — | — | — | — | — | — | — |
| Refractory | — | — | — | — | — | — | — | — |
| Untreated/unknown | — | — | — | — | — | — | — | — |
| Conditioning | ||||||||
| MAC vs RIC/NMA | — | — | 1.56 (0.93-2.62) | .08911 | — | — | — | — |
| GVH prevention (ref = post-Cy ± other[s]) | ||||||||
| CNI + MMF or MTX ± other(s) (except post-Cy) | 1.99(1.36-2.92) | .00037 | — | — | 2.01(1.45-2.78) | <.0001 | — | — |
| KPS | ||||||||
| <90 vs ≥90 | — | — | — | — | — | — | — | — |
| HCT-CI (ref = 0) | ||||||||
| 1-2 | — | — | — | — | — | — | — | — |
| ≥3 | — | — | — | — | — | — | — | — |
| Variables . | OS . | PFS . | RI . | NRM . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Age | ||||||||
| 1 year increase | 1.03(1.02-1.04) | <.0001 | 1.03(1.02-1.04) | <.0001 | — | — | 1.03(1.02-1.05) | <.0001 |
| Year of HCT | ||||||||
| 1 year increase | 1.05 (0.94-1.18) | .36319 | 1 (0.9-1.1) | .94469 | — | — | 1 (0.87-1.14) | .9598 |
| Sex | ||||||||
| Female vs male | — | — | — | — | — | — | — | — |
| Donor type (ref = HLA-id sib) | ||||||||
| Haploidentical donor | 1.73 (0.98-3.05) | .05682 | — | — | — | — | — | — |
| HLA-MUD | 0.87 (0.53-1.45) | .59567 | — | — | — | — | — | — |
| Prior auto | ||||||||
| Yes vs no | — | — | — | — | — | — | — | — |
| Disease status (ref = CR) | ||||||||
| PR | 1.66(1.12-2.48) | .01179 | 1.46(1.02-2.08) | .03893 | 1.48 (0.84-2.62) | .17789 | — | — |
| Refractory | 2(1.25-3.18) | .00374 | 1.82(1.2-2.77) | .00521 | 3.03(1.66-5.56) | .00033 | — | — |
| Conditioning | ||||||||
| MAC vs RIC/NMA | 1.23 (0.78-1.94) | .37907 | — | — | — | — | — | — |
| GVHD prevention (ref = post-Cy ± other[s]) | ||||||||
| CNI + MMF or MTX ± other(s) (except post-Cy) | 1.84(1.09-3.12) | .0223 | 1.29 (0.94-1.78) | .10962 | — | — | 1.33 (0.87-2.02) | .18293 |
| KPS | ||||||||
| <90 vs ≥90 | — | — | — | — | 1.85(1.1-3.1) | .02027 | — | — |
| HCT-CI (ref = 0) | ||||||||
| 1-2 | — | — | — | — | — | — | — | — |
| ≥3 | — | — | — | — | — | — | — | — |
| Variables | aGVHD 2-4 | aGVHD 3-4 | cGVHD | Engraftment | ||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Age | ||||||||
| 1 year increase | — | — | — | — | 1.01 (1-1.03) | .0466 | 0.99 (0.99-1) | .04942 |
| Year of HCT | ||||||||
| 1 year increase | — | — | 1.03 (0.9-1.17) | .66482 | 1.03 (0.92-1.15) | .57891 | 1.18 (0.98-1.43) | .08193 |
| Sex | ||||||||
| Female vs male | — | — | 0.81 (0.5-1.3) | .37633 | — | — | — | — |
| Donor type (ref = HLA-id sib) | ||||||||
| Haploidentical donor | 2.1(1.37-3.22) | .00063 | — | — | — | — | — | — |
| HLA-MUD | 0.91 (0.6-1.38) | .65396 | — | — | — | — | — | — |
| Prior auto | ||||||||
| Yes vs no | 0.67 (0.51-0.9) | .007 | — | — | — | — | 1.18 (0.98-1.43) | .08193 |
| Disease status at conditioning (ref = CR) | ||||||||
| PR | — | — | — | — | — | — | — | — |
| Refractory | — | — | — | — | — | — | — | — |
| Untreated/unknown | — | — | — | — | — | — | — | — |
| Conditioning | ||||||||
| MAC vs RIC/NMA | — | — | 1.56 (0.93-2.62) | .08911 | — | — | — | — |
| GVH prevention (ref = post-Cy ± other[s]) | ||||||||
| CNI + MMF or MTX ± other(s) (except post-Cy) | 1.99(1.36-2.92) | .00037 | — | — | 2.01(1.45-2.78) | <.0001 | — | — |
| KPS | ||||||||
| <90 vs ≥90 | — | — | — | — | — | — | — | — |
| HCT-CI (ref = 0) | ||||||||
| 1-2 | — | — | — | — | — | — | — | — |
| ≥3 | — | — | — | — | — | — | — | — |
We performed a stepwise selection procedure for inclusion of the variables in the models. Not all covariates are included for all outcomes. Bold type highlights significant results.
CNI, calcineurin inhibitor; MMF, mycophenolate mofetil; MTX, methotrexate; ref, reference.